Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2012 Nov 18;137(1):93–107. doi: 10.1007/s10549-012-2332-x

Fig. 7. Gene expression changes in the NF-κB signaling pathway in AI-resistant cell lines.

Fig. 7

Fig. 7

(A) LBH589 treatment significantly reduced NF-κB1 mRNA expression. MCF-7aro, LTEDaro, Exe-R, Let-R and Ana-R cells were treated with 20 nM LBH589 for 24 hours. Real-time PCR was performed to evaluate changes in gene expression. Gene expression was normalized to β-actin. *, p < 0.01. (B) Base-line NF-κB1 mRNA expression was higher in T47DaroLTED cells than in T47Daro cells, and decreased in both cell lines after LBH589 treatment. Cells were treated with 20 nM LBH589 for 24 hours, and NF-κB1 mRNA expression was analyzed by real time PCR. Gene expression was normalized to β-actin. *, p < 0.05; **, p < 0.01. (C) MCF-7aro and Exe-R were treated with 20 nM LBH589 for 16 hours, and total RNA was extracted at the indicated time points. Real-time PCR was used to assess expression of NF-κB1, RelA, NF-κB target genes (CFLAR and CCND1), and CDKN1A. Gene expression was normalized to β-actin mRNA. Data are expressed as a ratio of treated samples to untreated controls and shown as mean ± SE.